Crohn's Disease Market Size is anticipated to grow at a CAGR of 7.6% for the study period 2018-2030 | DelveInsight

Crohn's disease is a type of inflammatory bowel disease (IBD). It is an inflammatory condition of the gastrointestinal tract, which most commonly affects the end of the small bowel (the ileum), the beginning of the colon, and any part of the gastrointestinal (GI) tract from the mouth to the anus. Additionally, ulcerative colitis, an IBD that causes long-lasting inflammation and ulcers (sores) in your digestive tract, is limited to the colon, also called the large intestine. CROHN'S DISEASE is characterized by skip intestinal lesions (that is, areas of inflammation interposed between normal-appearing mucosa) anywhere in the GI tract. It involves chronic, relapsing transmural inflammation that can lead to Chronic abdominal pain, diarrhea, obstruction and/or perianal lesions.

DelveInsight's 'Crohn's Disease Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Crohn's Disease, historical and forecasted epidemiology as well as the Crohn's Disease market trends in the United States.

To get detailed information about Crohn's Disease Market Dynamics, Click here @ https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of Crohn's Disease Market are:

• In the year 2020, the total prevalent case of Crohn's Disease was 825,165 cases in the United States which are expected to grow during the forecast period, i.e., 2021-2030.

• The disease epidemiology covered in the report provides historical as well as forecasted Crohn's Disease epidemiology [segmented as Total Prevalent Cases of Crohn's Disease, Total Diagnosed Cases of Crohn's Disease, Age-specific cases of Crohn's Disease, Severity-specific Cases of Crohn's Disease, and Treated cases of Crohn's Disease] in the United States from 2018 to 2030.

• The US FDA-approved biologics for the treatment of Crohn's Disease include infliximab, adalimumab, certolizumab, vedolizumab, natalizumab, ustekinumab.

• Growth of the Crohn's Disease market is expected to be mainly driven by the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/advanced therapies, advances in research and development, new biomarkers for diagnosis of Crohn's Disease, and increasing prevalence of Crohn's Disease.

To get detailed information about Crohn's Disease Epidemiology Insight, Click here @ https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Crohn's Disease Report Scope

• The report covers the descriptive overview of Crohn's Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
• Comprehensive insight has been provided into the Crohn's Disease epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Crohn's Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Crohn's Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Crohn's Disease market.

Crohn's Disease Therapies covered:

• Jyselica/Filgotinib (Gilead Sciences/Galapagos NV)
• Rinvoq/Upadacitinib (AbbVie)
• Etrolizumab/RG 7413 (Hoffmann-La Roche/Genentech)
• Ozanimod/Zeposia (Celgene)
• Skyrizi/Risankizumab (AbbVie/Boehringer Ingelheim)
• Brazikumab/MEDI-2070 (Astrazeneca)
• Alofisel/Darvadstrocel (Takeda/TiGenix)
• Mirikizumab/LY-3074828 (Eli Lilly and Company)
• RHB-104 (RedHill Biopharma)
• Etrasimod/APD334 (Arena Pharmaceuticals)
• Tremfya/Guselkumab (Janssen)
• Deucravacitinib/BMS-986165 (Bristol-Myers Squibb)
• Tesnatilimab/JNJ-64304500 (Janssen)
• Sibofimloc/EB8018 (Takeda/Enterome)
• BT-11 (Landos Biopharma)
• UTTR1147A/RG 7880 (Genentech)
• TD-1473/JNJ 8398 (Theravance Biopharma/Janssen)
• JNJ-67864238/PTG 200 (Protagonist Therapeutics/Janssen)
• SHR0302 (Reistone Biopharma)
• Ryoncil/Remestemcel-L (Mesoblast)
• Ritlecitinib/Brepocitinib (Pfizer)

Click here to get detailed information about Crohn's Disease Therapies and Treatment, Click here @ https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of content

1. Key Insights
2. Executive Summary of Crohn's Disease
3. Competitive Intelligence Analysis for Crohn's Disease
4. Crohn's Disease: Market Overview at a Glance
5. Crohn's Disease: Disease Background and Overview
6. Patient Journey
7. Crohn's Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Crohn's Disease Treatment
11. Marketed Products
12. Emerging Therapies
13. Crohn's Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Crohn's Disease
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Request for Detailed TOC: To get detailed information about Crohn's Disease Market Dynamics, Click here @ https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech, and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Contact Us
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.